

YOUR INVITATION TO ATTEND:

# GeneSight® in Clinical Practice

## A MYRIAD GENETICS SPEAKER PRESENTATION

*A clinical and scientific discussion focusing on the basics of pharmacogenomics and review of the GeneSight® Psychotropic report and clinical data. Q&A to follow.*



### PRESENTER

Ingrid Cook, APRN, PMHNP-BC,  
CPNP-PC

Ingrid Cook, APRN, PMHNP-BC, CPNP-PC, PMHS, CAS is a triple board-certified nurse practitioner in psychiatric mental health, pediatric primary care, and pediatric mental health in addition to being a certified autism specialist with over 33 years of nursing experience. Ingrid is a graduate of Northwestern State University where she obtained her Master of Science in Nursing as a Pediatric Nurse Practitioner and then completed her post-master's certification in Psychiatric Mental Health. She has practiced in child and adolescent psychiatry in the outpatient, inpatient, telepsychiatry and therapeutic group home settings. Ingrid has authored a book chapter, "Behavioral Pediatric Healthcare for Nurse Practitioner: A Growth and Development Approach to Intercepting Abnormal Behaviors" and is an exam item writer for the National Pediatric Nursing Certification Board (PNCB) for Pediatric Nurse Practitioners. She is also a member of the American Association of Nurse Practitioners (AANP), Association of Psychiatric Mental Health Nurse Practitioners (APMHNP) and Louisiana Association of Nurse Practitioners (LANP). Ingrid retired from the U.S. Navy after serving 31 years including multiple deployments.

### DATE & TIME

Thursday, March 12, 2026  
6:00pm

### LOCATION

Monroe's  
1301 N 19th St  
Monroe, LA 71201

### QUESTIONS

George Johnson  
Sales Executive  
george.johnson@myriad.com  
(225) 936-5335

### RSVP

Please RSVP by  
**March 10, 2026**

### TO REGISTER

Click [Here](#) or scan  
the QR code below



*This event is not open to the general public. If you were not the original recipient of this invitation, please contact a GeneSight representative with your request to attend.*

The GeneSight® Psychotropic test is a genetics-based decision support tool that analyzes clinically important genetic variations that may affect your patient's outcomes with certain psychiatric medications. Use of the GeneSight Psychotropic test can help inform your medication selection. The results show which medications may require dose adjustments, may be less likely to work, or may have an increased risk of side effects based on your patient's genetic makeup. The clinical validity, clinical utility, and economic utility of the GeneSight Psychotropic test have been evaluated in seven published, peer-reviewed clinical trials. In the GUIDED study, patients in the GeneSight arm experienced an 11% relative improvement in symptoms, a 30% relative improvement in response rates, and a 50% relative improvement in remission rates compared to treatment as usual at week 8.

**Myriad**  
genetics

6980 Centex Blvd  
Mason, OH 45040  
888.240.2384

 **genesight**  
www.genesight.com

© 2021 Assurex Health, Inc. doing business as Myriad Neuroscience. GeneSight and associated logos are registered trademarks of Assurex Health, Inc. All rights reserved.  
MS21-005 v.19